2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2014 Featured Talks » Preclinical and early clinical activity of STAT3RX/AZD9150, A NEXT GENERATION ANTISENSE OLIGONUCLEOTIDE TARGETING STAT3



Part One

Part Two

Preclinical and early clinical activity of STAT3RX/AZD9150, A NEXT GENERATION ANTISENSE OLIGONUCLEOTIDE TARGETING STAT3


Robert MacLeod, PhD
Isis Pharmaceuticals




Robert MacLeod, PhD
Vice President, Oncology & Exploratory Discovery
Isis Pharmaceuticals